Intelligent, e±cient silica nanoparticles for drug delivery system in cancer therapy have a great application potential, but the biodegradability of silica nanoparticles becomes an intractable hindrance. In this work, novel reactive oxygen species (ROS)-responsive hollow mesoporous organosilica nanoparticles (HMONs) coated with polydopamine (PDA) bio¯lm and aminoterminated methoxy poly(ethylene glycol) (mPEG-NH 2 Þ were synthesized and applied in the smart drug delivery system (HMONs@PDA-mPEG) for the delivery of doxorubicin (DOX). The nanostructures and morphologies of nanoparticles were characterized by Fourier transform infrared (FTIR) spectroscopy, transmission electron microscopy (TEM), scanning electron microscopy (SEM), N 2 adsorption/desorption, dynamic light scattering (DLS) and thermogravimetric analysis. Based on the \chemical homology" mechanism, physiologically active thioacetal-bridged silsesquioxane was molecularly incorporated into the framework of silica nanoparticles to form ROS-responsive HMONs, which was veri¯ed by the in vitro degradation experiment. The in vitro drug release pro¯les showed a synergistically pH-dependent and ROSresponsive drug release e®ect. MTT assay toward A549 cells demonstrated that drug carriers had a biocompatibility, and DOX-loaded nanoparticles (DNs) presented a concentrationdependent and time-dependent cell growth inhibition e®ect. In summary, the novel ROSresponsive HMONs@PDA-mPEG had a promising application as a smart drug delivery system in biomedical¯eld.
Introduction
Nanotechnology, a novel approach for cancer diagnosis and therapy, encourages researchers to explore the potential nanomaterials to tackle the increasingly severe cancer problem. 1 As one of the most twinkling nanomaterials in the biomedicinē eld, mesoporous silica nanoparticles (MSNs) have attracted enormous attention since the¯rst attempt in 2001 of M41S-type ones as drug carriers for their versatile chemical properties, such as controllable morphologies and nanostructures, ample surface functional sites and good biocompatibility. [2] [3] [4] Many groundbreaking results have been reported based on the design of more accurate nanostructures 5, 6 and more practical applications. 7, 8 However, the poor degradability of inorganic Si-O-Si framework of MSNs under natural physiological microenvironment is still an unavoidably inherent°aw for clinical application, which brings tremendous uncertainties after intravenous injection into the blood because of the potential nanotoxicity of nanoparticles accumulated in the reticuloendothelial system (including important organs such as liver, spleen, lung) for a relatively long time. 9, 10 Mesoporous organosilica nanoparticles (MONs), which homogeneously incorporate organo-bridged silsesquioxane and inorganic Si components, endow the inorganic nanoparticles with synergistic advantages of organic and inorganic ingredients, and have been generally regarded as the promising substitute to MSNs for clinical translation. 11 MONs could be tailored as the speci¯c nanoparticles to meet the strict demands of structure characteristics for biomedicine applications by adjusting various conditions and parameters of synthesis, such as the ratio of organic and inorganic components, species of organic moieties, species and concentrations of soft template. [12] [13] [14] For instance, the disul¯de bonds introduced into the single Si-O-Si structure could have been e®ectively cleaved by the abundant glutathione (GSH) in intracellular microenvironment to accelerate the collapse of skeleton into fragmented debris for rapid clearance. 15 MONs with di®erent organic moieties inside the framework will exhibit corresponding stimuli-responsive chemistry properties under di®erent cancer microenvironment, as a result causing desirable e®ects like improving e±ciency of endocytosis, accelerating biodegradation, intelligently releasing chemical mediator. 16, 17 Among various stimuli-responsive nanomaterials, ROS-responsive MONs embody special advantages that inspire immense research enthusiasm.
Reactive oxygen species (ROS), such as hydroxyl radicals (OHÁ), hydrogen peroxides (H 2 O 2 Þ, peroxynitrites (ONOO À Þ, and superoxides (O 2À Þ, are a series of small molecules with powerful oxidation capacity widely distributed in human cells and play a crucial role in many physiological processes (including gene expression, signal transduction, metabolic equilibrium, immune reactions, etc.). 18, 19 In the normal cells, ROS commonly maintain at relatively low concentration (% 20 Â 10 À9 M), however, there is much evidence to suggest that the contents of ROS in many kinds of tumor cells have a huge elevation (% 100 Â 10 À6 M) because of the oncogenic stimulation and hypoxia. [20] [21] [22] Such enormous differences of ROS concentration have been considered as the representative hallmark of tumor cells and provide an applicable possibility of designing a class of ROS-responsive materials for cancer therapy. 23 Many ROS-sensitive moieties like thioether, thioketal, boronic ester and arylboronic ester have been utilized to respond to high concentration of ROS as the amphiphilic polymer prodrug or as the cleavable site between carriers and functional molecules for smart drug delivery system. 24, 25 Encouraged by the above positive progress, we speculate that molecularly incorporating ROS-sensitive moieties with thioacetal structure into the framework of MSNs to fabricate ROS-responsive HMONs as the drug carrier might be a feasible program for cancer therapy.
In this work, we reported a novel smart drug delivery system with biocompatibility, ROS-responsive biodegradability and synergistic drug release properties for cancer therapy. A new thioacetal-bridged silsesquioxane, named as bis[3-(trimethoxysilyl)propyl](4-methoxyphenyl)thioacetal (BTMPTA), was rst synthesized as the precursor. Then, ROSresponsive HMONs were fabricated based on the \chemical homology" mechanism 26 and \ammoniaassisted selective etching" strategy 27 to endow biodegradability and to provide extra space for drug molecules. Doxorubicin (DOX) hydrochloride was chosen as the model drug for anticancer research. Polydopamine (PDA) was coated onto the surface of nanoparticles to form a pH-sensitive gatekeeper and intelligently release the drug at the desirable site. 28 Finally, amino-terminated methoxy poly(ethylene glycol) (mPEG-NH 2 Þ was anchored onto the surface of PDA-coated nanoparticles to further improve the biocompatibility. The synthesis route is represented in Scheme 1. The biochemical properties of the drug delivery system, including the drug-loading and releasing behavior, ROS-responsive biodegradability, cytotoxicity and anticancer activity, were further investigated.
Experimental Methods

Materials
Tetraethyl orthosilicate (TEOS), (3-Mercaptopropyl) trimethoxysilane (MPTMS), hexadecyl trimethyl ammonium bromide (CTAB), tri°uoroethanoic acid (TFA), triethanolamine (TEA), p-anisaldehyde, dopamine hydrochloride, ammonia solution (25-28%) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Aladdin Co., Ltd. Anhydrous ethanol, anhydrous sodium sulfate (Na 2 SO 4 Þ, dimethyl sulfoxide (DMSO), petroleum ether (PE), dichloromethane (DCM) and peroxide (30% H 2 O 2 Þ were purchased from Sinopharm Chemical Regent Co., Ltd. Aminoterminated methoxy poly(ethylene glycol) (Mn ¼ 2000) was purchased from Jenkem Technology Co., Ltd. DOX hydrochloride was purchased from Beijing Huafeng United Technology Co., Ltd. RPMI-1640 medium and fetal bovine serum (FBS) were purchased from Shanghai Xinyu Biological Technology Co., Ltd. A549 cell lines were obtained from Shanghai Institute of Biochemistry and Cell Biology.
Synthesis of bis[3-(trimethoxysilyl)
propyl](4-methoxyphenyl)thioacetal was monitored by thin layer chromatography until p-anisaldehyde was totally exhausted. The solution was orderly washed with saturated sodium chloride solution and saturated sodium bicarbonate. The organic layer was dried with anhydrous sodium sulfate and condensed on rotavap. The concentrate was added dropwise into iced PE with vigorous stirring. The mixture was placed in the fridge for 0.5 h. The supernatant was carefully removed into round°ask and condensed on rotavap. The puri¯cation process was repeated several times until there was little impurity in the supernatant. 1 
Synthesis of ROS-responsive HMONs
In order to construct the hollow nanoparticles with organic-inorganic hybrid framework, a modi¯ed procedure based on the previous literature was adopted. 29 Typically, 2.0 g CTAB and 0.08 g TEA were added into 20 mL deionized water and premixed at 95 C in a water bath for 0.5 h, then 1.0 mL TEOS was added dropwise to form monodispersed MSNs as the hard template after 1 h reaction. To coat the organic-inorganic hybrid layer onto the surface of MSNs, a mixture of 1.0 mL TEOS and 0.6 mL BTMPTA was added dropwise for further 4 h reaction. Then, the white product was collected by centrifugation (10 000 r, 15 min) and washed with anhydrous ethanol three times. To remove the CTAB, the white product was re-dispersed into a mixed solution (150 mL) of ethanol and concentrated HCl (37%) (V ethanol : V HCl ¼ 10 : 1) at 80 C for 24 h. Such extraction process was repeated several times until the CTAB was totally removed. The white product was washed with anhydrous ethanol three times to obtain CTAB-removed MSN@MONs and then re-dispersed into 20 mL anhydrous ethanol for further treatment. To form the hollow structure, an \ammonia-assisted selective etching" strategy was used. Above MSN@MONs mixture was added into 400 mL deionized water, followed by the addition of 8.0 mL ammonia solution. The etching process lasted for 3 h at 95 C. After naturally cooled to room temperature, the¯nal HMONs were collected by centrifugation (10 000 r, 15 min) and washed with anhydrous ethanol three times.
Loading drug into HMONs
To obtain the DOX@HMONs, 0.3 g HMONs and 60 mg DOX were ultrasonically dispersed in 60 mL phosphate bu®ered saline (PBS). The drug-loading process was executed in dark at room temperature with stirring for 24 h. The mixture solution was centrifuged (10 000 r, 15 min) and washed several times with deionized water to completely remove the excess DOX. The pink product was obtained by lyophilization and stored in the fridge. In order to calculate the loading content (LC), the supernatant and all the washed solution were collected for UV-Vis spectrophotometry analysis at the wavelength of 488 nm. LC was calculated by
Coating PDA onto the surface of DOX@HMONs
For the surface modi¯cation with PDA, 0.2 g DOX@HMONs were incubated in 100 mL Tris-HCl bu®er (pH 8.5, 10 mM) containing 0.1 g dopamine hydrochloride, and stirred in dark at room temperature for 6 h. The black mixture was centrifuged (10 000 r, 15 min), washed with deionized water to remove the unpolymerized dopamine and lyophilized to obtain DOX@HMONs@PDA. The blank sample (HMONs@PDA) was prepared by the same procedure.
Conjugation of mPEG-NH 2 to DOX@HMONs@PDA
The hydrophilic polymer with nucleophilic group was bound to the surface of DOX@HMONs@ PDA through Michael addition reaction. 0.15 g DOX@HMONs@PDA and 0.3 g mPEG-NH 2 were suspended in 20 mL Tris-HCl bu®er (pH 8.5, 10 mM) and stirred in dark at room temperature for 24 h. After that, the black mixture was centrifuged (10 000 r, 15 min), washed with deionized water several times to remove the remaining mPEG-NH 2 . The¯nal DOX@HMONs@PDA-mPEG was lyophilized for 48 h and stored in the fridge for further use. The HMONs@PDA-mPEG was prepared with the same procedure.
Characterization of nanoparticles
1 H and 13 C nuclear magnetic resonance spectra were recorded by nuclear magnetic resonance instrument (AVANCE III 400 MHz Bruker, Switzerland). The mass spectrometry experiment was performed using a LC-Q-TOF (MS, AB Sciex 4600, USA). The hydrodynamic particle-size distribution and Zeta potential of nanoparticles were detected by dynamic light scattering (DLS) instrument (Malvern Nana ZS 90, UK). The mesoporous structure and pore-size distribution were obtained on a Micrometitics instrument (Tristar II U3020, USA), and the data were analyzed with the Brunauer-Emmett-Teller (BET) method. The morphology of nanoparticles was characterized by¯eld emission scanning electron microscopy (SEM, Magellan 400, USA). The hollow structure of nanoparticles was observed by transmission electron microscopy (TEM, JEM-2100F, Japan). The mass ratio of nanoparticles was measured by a thermogravimetric analyzer (TGA, TG/DTA 7300, Japan). The functional group information of nanoparticles was recorded by Fourier transform infrared (FTIR, Nicolet 6700, USA). The content of organic component in solution was analyzed by UV-Vis adsorption spectroscopy (DR 6000, USA). The Si content from degraded HMONs was tested by inductively coupled plasma atomic emission spectrometry (ICP-AES, Optimal 2100DV, USA).
In vitro drug release pro¯les
The The centrifuge tubes were placed in an orbital shaker water-bath with constant temperature (37 C) and rotation rate (100 rpm). At the selected interval, the release solution of 2.0 mL outside the dialysis bag was taken out and then added with equal volume of corresponding fresh bu®er. The content of released DOX was determined by UV-Vis spectrophotometry analysis at the wavelength of 488 nm and the cumulative release rate of DOX was calculated by
where R is the cumulative release rate of DOX; V 0 and V e separately represent the volume of initial bu®er and exchanged volume; C n and C nÀ1 represent the DOX concentration in the release medium for n and nÀ1 times, respectively; W DOX is the weight of DOX in the DNs.
Biodegradation assay in PBS solution
To ascertain the ROS-responsive degradation behavior of HMONs, 25 mg HMONs were incubated in a simulated ROS microenvironment (50 mL PBS with 500 mM H 2 O 2 and 3.2 M CuCl 2 Þ at 37 C under slow stirring and a control group without ROS environment was implemented simultaneously. 30 At the selected time, 1.5 mL solution was taken out and centrifuged. The supernatant was analyzed by ICP-AES for Si content and the precipitant was detected by DLS for hydrodynamic particle-size distribution. A similar procedure was executed except a mixture of PBS and ethanol (V PBS : V ethanol ¼ 9 : 1) instead of pure PBS, the supernatant was collected for p-anisaldehyde detection by UV-Vis spectrophotometry analysis. In addition, HMONs@PDA-mPEG was also estimated to provide the evidence of biodegradability and the process was similar with the evaluation process of HMONs.
In vitro cytotoxicity assessment
MTT assay was adopted to evaluate the cytotoxicity of HMONs, HMON@PDA and HMON@PDA-mPEG against A549 cells. 200 L culture medium containing 10% FBS was added to the 96-well plate at the cell density of 1 Â 10 4 per well and incubated for 24 h. Then the culture medium was carefully removed and 200 L fresh culture medium containing di®erent concentrations of nanoparticles (12.5, 25, 50, 100 and 200 g/mL) was added for additional 24 h. The culture medium was replaced with the mixture of 90 L blank culture medium and 10 L MTT (5 mg/mL). After co-incubation for 4 h, the culture medium was completely removed and 150 L DMSO was added to dissolve the resulting crystals under mildly shaking for 10 min. The absorbance of each well was obtained by microplate reader at the wavelength of 490 nm to calculate the cell viabilities.
In vitro anticancer activity
The anticancer activity of DOX@HMONs, DOX@ HMONs@PDA and DOX@HMONs@PDA-mPEG was estimated by MTT assay against A549 cells.
The experiment process was similar to the experiment of cytotoxicity assessment except a substitution of pure drug carrier by the culture medium with di®erent concentrations of DNs. The free DOX was used as a control.
Results and Discussion
Synthesis of DOX@HMONs@ PDA-mPEG
The design strategy of DOX@HMONs@PDA-mPEG was depicted in Scheme 1. BTMPTA was synthesized by the typical nucleophilic addition reaction. To obtain the HMONs, a similar process was adopted with slight modi¯cation according to the literature issued previously. 29 The monodispersed MSNs were initially synthesized as the hard template, then an organic-inorganic hybrid layer was coated onto the surface of MSNs to form coreshell MSN@MONs, and next, the inner -Si-O-Sistructure was selectively etched away by ammonia solution to attain¯nal HMONs. Subsequently, DOX was loaded into the cavity of HMONs by di®usion after fully mixing in an aqueous solution for 24 h. After that, PDA was coated onto the surface of DOX@HMONs by the oxidative selfpolymerization of dopamine in the weak alkaline condition. Finally, DOX@HMONs@PDA were functionalized by mPEG-NH 2 to form PEGylated nanocomposite.
Characterization of nanoparticles
MSNs were synthesized as the hard template in size of about 35 nm [ Fig. 1(a) ]. Based on the \chemical homology" mechanism and \ammonia-assisted selective etching" strategy, HMONs were fabricated and the hollow structure was observed in TEM image [ Fig. 1(b) ], in which the darker edge of each HMONs represented the intact spherical shell, and the light middle part represented the hollow cavity. The size of hollow cavity of HMONs is slightly larger than the size of MSNs, which could be the result of over-etching. The homogeneous hybridization within the framework of HMONs was conrmed by the energy dispersive spectrometer (EDS) element area mapping The size and ZP of all nanoparticles were determined through DLS. As shown in Table 1 , the size and PDI of HMONs, DOX@HMONs, DOX@H-MONs@PDA and DOX@HMONs@PDA-mPEG were 88:4 AE 2:3 nm (PDI ¼ 0:123), 97:5 AE 3:6 nm (PDI ¼ 0:161), 110:4 AE 3:4 nm (PDI ¼ 0:208) and 130:7 AE 4:3 nm (PDI ¼ 0:275), respectively. The increasing size in turn was due to the success of loading drug, coating PDA and incorporating mPEG-NH 2 . Meanwhile, the size of all nanoparticles is less than 200 nm, which was appropriate as the biomedicine for the potential application based on the crucial principle of enhanced permeability and retention e®ect. 31 Further more, the ZP of HMONs, DOX@HMONs, DOX@HMONs@PDA and DOX@HMONs@PDA-mPEG were À25:5AE 0:4 mV, À18:6AE 1.5 mV, À15:4 AE 0:8 mV and À16:1 AE 0:5 mV, respectively. The negative ZP of HMONs mainly be attributed to the plenty of negatively charged silanol groups inside the framework. Compared with the HMONs, the ZP of DOX@HMONs increased to À18:6 AE 1:5 mV, which may be ascribed to the amino groups on DOX neutralizing the partial of the silanol groups. After coated PDA onto the surface, the ZP of DOX@HMONs@PDA was changed to À15:4 AE 0:8 mV, which was due to the deprotonation of phenolic hydroxyl groups after the self-polymerization of dopamine. After functionalization by mPEG-NH2, the ZP of DOX@H-MONs@PDA-mPEG became À16:1 AE 0:5 mV. All the nanoparticles showed a slightly negative charge, which was bene¯cial to improve their dispersibility and cell accessibility. 32 Besides, in the continuous The mesoporous features of HMONs were measured by N 2 adsorption/desorption analysis. As shown in Fig. 2(a) , the N 2 adsorption/desorption curve displayed a typical type-IV isotherm with H1 hysteresis loop. The BET surface area, pore volume and the most probable pore size were 125.4 m 2 g À1 , 0.52 cm 3 g À1 and 11.1 nm, respectively. The relatively small BET surface area and relatively large pore size may be explained by the synergistic e®ect of three aspects. First, BTMPTA had a slow hydrolysis and condensation rates compared with TEOS. At the beginning of the reaction, a trace of hydrolyzed BTMPTA with hydrophobic chains mainly acted as the swelling agent rather than reactant, and penetrated into the hydrophobic CTAB micelles to form an enlarged co-micelle. Second, the rigid benzene ring group inside the structure of BTMPTA increased the steric e®ect, which means that the mesopore formed onto the surface of co-micelle would be further enlarged. Third, according to the phenomenon that the hollow cavity of HMONs is larger than the hard template, it could be inferred that over-etching process caused more enlarged mesopore. Similar studies about the role of organo-bridged precursor in the structure formation of nanoparticles had been reported previously. [33] [34] [35] The homogeneous incorporation of thioacetalbridged silsesquioxane into the framework of MSNs was further veri¯ed. As shown in Fig. 3(a) , both of the tested nanoparticles exhibited the typical characteristic peaks of silica materials at 790 cm À1 , 960 cm À1 and 1095 cm À1 , which could be assigned to the Si-OH stretch, Si-O vibration and Si-O-Si symmetrical stretch, respectively. Compared with the MSNs, HMONs had some unique absorption peaks. Peaks at 1505 cm À1 and 1450 cm À1 were corresponded to the aromatic ring skeleton stretching vibration, while peak at 1240 cm À1 was due to the C-O-C asymmetrical stretch, and peak at 1162 cm À1 could be attributed to the Si-C stretch. All the new absorption peaks of HMONs were consistent with the characteristic absorption peaks of BTMPTA, which was the crucial precursor of HMONs. Moreover, from the UV-Vis absorbance curves of MSNs, HMONs and BTMPTA [ Fig. 3(b) ], an obvious absorption peak at $ 290 nm of HMONs and BTMPTA was observed, but no distinct absorption peak of MSNs was observed. This result was mostly due to the°uorescence e®ect of p-anisaldehyde derivative inside the framework of HMONs and BTMPTA. The results from FTIR and UV-Vis absorbance curves provided convictive evidences of successful construction of HMONs with molecularly hybridized framework.
TGA was performed to illustrate the quantitative di®erence of various nanoparticles after heating. As shown in Fig. 3(c bare MSNs, MSN@MONs and HMONs were consistent with the fact of decreasing inorganic components and increasing organic components inside the skeleton of those nanoparticles, which further indicated a successful construction of HMONs by the \chemical homology" mechanism and \ammonia-assisted selective etching" strategy. After surface functionalization of HMONs, the weight loss further enlarged to 34.89 wt.% for HMONs after coated with PDA and 38.72 wt.% for HMONs@PDA after incorporated with mPEG-NH 2 in the same temperature range. Those results jointly demonstrated that HMONs@PDA-mPEG were successfully synthesized.
In vitro degradation
To demonstrate the ROS-responsive degradation behavior of HMONs, nanoparticles were incubated in the simulated ROS microenvironment, and a control group without ROS environment was implemented simultaneously. Theoretically, the thioacetal bonds in the HMONs framework will be cleaved under the ROS environment, thus cause the collapse of structure [ Fig. 4(a) ]. As shown in Fig. 4(b) , the hydrodynamic size of HMONs in the simulated ROS microenvironment had a rapid decrease from initial 84.5 nm to 44.8 nm in 96 h, and a slow decreasing tendency was observed until the size Fig. 4(c) ]. However, the size of control group only had a slight decrease from 84.5 nm to 80.4 nm, and the PDI basically keep changeless. The inverse trend was observed that the Si content [ Fig. 4(d) ], which degraded from HMONs in PBS and determined by ICP-AES, had a rapid increase in 96 h, and then, reached the maximum (about 68.5%) with a slow speed after 192 h in the simulated ROS microenvironment, while the Si content in control group only reached about 5.4% after 192 h. Furthermore, with the prolongation of time, the variation trend of UV-Vis absorbance intensity of p-anisaldehyde [ Fig. 4(e) ], which was released from the degraded hybrid framework into the solution, was consistent with the variation trend of Si content. HMONs@PDA-mPEG was executed to illustrate that HMONs still maintained the biodegradability after the surface functionalization. As shown in Fig. 4(f) , the structure of HMONs@ PDA-mPEG only showed light change after 1 days. After 3 days, degradation became evident that the shape of nanoparticles was changed and the number of fragments of nanoparticles increased [ Fig. 4(g) ]. After 5 days, almost no intact nanoparticles could be observed [ Fig. 4(h) ]. After 7 days, all the nanoparticles became the debris and piled together, making it di±cult to distinguish [ Fig. 4(i) ]. Those results all demonstrated that synthesized nanoparticles with abundant thioacetal structures could be e®ectively degraded by ROS and had a potential as the stimuli-responsive material for bioapplication.
In vitro drug release
To investigate the in vitro drug release behavior triggered by pH and ROS, DOX release experiments of DOX@HMONs, DOX@HMONs@PDA and DOX@HMONs@PDA-mPEG in di®erent conditions were executed. As shown in Fig. 5 , a typically biphasic release pattern was observed in all of the drug release curves that an initial burst release of DOX within 24 h followed by a slowly sustained drug release to the end. For the PDA-coated nanoparticles (DOX@HMONs@PDA and DOX@ HMONs@PDA-mPEG), the drug release rates were lower than that of DOX@HMONs in each condition. The drug release rates were 18.5% and 16.4% at pH 7.4 and 38.6% and 34.6% at pH 5.0 for DOX@HMONs@PDA and DOX@HMONs@PDA-mPEG, respectively, while the drug release rate of 
In vitro cytotoxicity and anticancer activity
The in vitro anticancer activity of DNs against A549 cells were assessed by MTT assay, and the cytotoxicity of DOX-free carriers (HMONs, HMONs@PDA and HMONs@PDA-mPEG) were investigated simultaneously to exclude any non-speci¯c e®ect. As shown in Fig. 6(a) , after incubated for 48 h with di®erent concentrations (12.5, 25, 50, 100, 200 g/mL) of various nanoparticles, the cell viabilities remained above 80% with no signi¯cant decrease, indicating that nanoparticles used in the experiment had a biocompatibility for the potential application as the drug carrier. As shown in Figs. 6(b) and 6(c), the cell viabilities of A549 cells which were incubated with free DOX and DNs at drug equivalent concentrations for 24 h and 48 h, respectively, could be effectively depressed with the prolonged time and the increased DNs concentration, which indicated a concentration-dependent and time-dependent cell growth inhibition e®ect. Compared with the DOX@HMONs, both the DOX@HMONs@PDA and DOX@HMONs@PDA-mPEG exerted lower cytotoxicity e®ects toward the A549 cells, which was mostly due to the blocked mesochannels by PDA bio¯lm caused a sustained but slow drug release. In addition, the cytotoxicity of DOX@H-MONs@PDA-mPEG was higher than that of DOX@HMONs@PDA, which was attributed to the enhanced biocompatibility endowed by the hydrophilic mPEG. Interestingly, the free DOX also exhibited highest cytotoxicity than that of DNs in this system, where similar results were reported by the previous papers. 28, 36 However, free DOX can cause severe side e®ects to normal cells. In contrast, DNs can e®ectively encapsulate the DOX and deliver it to the desirable sites without pre-leakage, which could be an appropriate method to exert advantages of DOX while to avoid the extra damages.
Conclusion
In this study, we successfully synthesized a novel ROS-responsive biodegradable nanocomposite (DOX@HMONs@PDA-mPEG) with synergistic drug release performance for cancer therapy. Based on the \chemical homology" mechanism and \ammonia-assisted selective etching" strategy, molecularly organic-inorganic hybrid HMONs were constructed using the thioacetal-bridged silsesquioxane. Homogeneous incorporation in the framework of HMONs was veri¯ed by EDS and FTIR, while hollow structure and monodispersed morphology were clearly observed via TEM. The in vitro degradation experiment in the simulated ROS microenvironment demonstrated that the thioacetal-bridged HMONs had a responsiveness to ROS. The in vitro drug release pro¯les revealed that DOX@HMONs@PDA-mPEG had a synergistic drug release e®ect under the pH and ROS microenvironment. The assessment of in vitro cytotoxicity and anticancer activity showed that HMONs@ PDA-mPEG were biocompatible and DOX@HMONs@PDA-mPEG had a good cell growth inhibition e®ect with the time dependence and concentration dependence. This work provides a paradigm of synthesizing thioacetal-bridged HMONs with abundant functionalities and unique characteristics as the drug carrier, which foresees a promising potential for biomedical application.
